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Abstract 135 
Objective: Genome-wide association studies (GWAS) have been successful at identifying 136 
associations with stroke and stroke subtypes, but have not yet identified any associations 137 
solely with small vessel stroke (SVS). SVS comprises a quarter of all ischaemic stroke and is 138 
a major manifestation of cerebral small vessel disease, the primary cause of vascular 139 
cognitive impairment. Studies across neurological traits have shown younger onset cases 140 
have an increased genetic burden. We leveraged this increased genetic burden by 141 
performing an age-at-onset informed GWAS meta-analysis, including a large younger onset 142 
SVS population, to identify novel associations with stroke.  143 
Methods: We used a three-stage age-at-onset informed GWAS to identify novel genetic 144 
variants associated with stroke. On identifying a novel locus associated with SVS, we 145 
assessed its influence on other small vessel disease phenotypes, as well as on mRNA 146 
expression of nearby genes, and on DNA methylation of nearby CpG sites in whole blood 147 
and in the fetal brain. 148 
Results: We identified an association with SVS in 4,203 cases and 50,728 controls on 149 
chromosome 16q24.2 (OR(95% CI)=1.16(1.10-1.22); p=3.2x10-9). The lead SNP 150 
(rs12445022) was also associated with cerebral white matter hyperintensities (OR(95% 151 
CI)=1.10(1.05-1.16); p=5.3x10-5; N=3,670), but not intracerebral haemorrhage (OR(95% 152 
CI)=0.97(0.84-1.12); p=0.71; 1,545 cases, 1,481 controls). rs12445022 is associated with 153 
mRNA expression of ZCCHC14 in arterial tissues (p=9.4x10-7), and DNA methylation at 154 
probe cg16596957 in whole blood (p=5.3x10-6).  155 
Interpretation: 16q24.2 is associated with SVS. Associations of the locus with expression of 156 
ZCCHC14 and DNA methylation suggest the locus acts through changes to regulatory 157 
elements.  158 
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Introduct ion 159 
Genome-wide association studies (GWAS) enable identification of common genetic variants 160 
that influence disease risk and have proved successful in elucidating pathophysiological 161 
mechanisms underlying diseases with a genetic influence.1 A number of GWAS associations 162 
have recently been identified with ischaemic stroke, almost all of which have been 163 
associated with specific stroke subtypes.2-4 A number of genetic associations have been 164 
reported with cardioembolic (CE) and large artery stroke (LAS), but in contrast there have 165 
been no robust associations solely with small vessel stroke (SVS). This is despite 166 
epidemiological data that suggest genetic factors are particularity important for SVS. For 167 
example, there are a number of monogenic stroke disorders associated with SVS,5 and 168 
family history studies have shown a strong association between SVS and a family history of 169 
stroke.6 Similarly, related traits, including white matter hyperintensities, have been shown to 170 
have high heritability.7 171 
 172 
SVS itself comprises a quarter of all ischaemic stroke and is one of the clinically overt 173 
manifestations of cerebral small vessel disease (SVD), the major cause of vascular cognitive 174 
impairment. Other radiological features of SVD include white matter hyperintensities (WMH) 175 
best seen on T2-weighted MRI, cerebral microbleeds - seen on gradient echo MRI, and 176 
intracerebral hemorrhages (ICH).8 Despite its importance, the pathogenesis of SVD remains 177 
poorly understood and this limits the development of proven treatments for established 178 
disease.   179 
 180 
One consistent finding across adult-onset neurological complex diseases including 181 
Parkinson’s disease,9 Alzheimer’s disease,10 and stroke,11 is that younger onset cases have 182 
a stronger genetic burden from common disease-associated SNPs. Leveraging this 183 
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increased burden, by focussing on younger onset cases in analysis of genetic data, can lead 184 
to detection of novel trait-associated variants.11 This may be particularly relevant for SVS, as 185 
epidemiological studies have shown stronger associations with SVS and a family history of 186 
stroke in younger stroke cases.6 187 
 188 
Here, we perform an age-at-onset informed GWAS meta-analysis in stroke, including a large 189 
population of younger onset (age<70) small vessel stroke (SVS) cases. We perform analysis 190 
for all ischaemic stroke (IS) and its three subtypes: cardioembolic (CE), large artery stroke 191 
(LAS) and SVS. Using this approach we identify a novel association with SVS, seek further 192 
validation of the locus in other SVD phenotypes, and assess the influence of SNPs at the 193 
locus on mRNA expression of nearby genes and DNA methylation at nearby CpG sites. 194 
 195 
Methods 196 
Study design 197 
We employed a three-stage design for the association analysis (Figure 1). In brief, in stage I 198 
we performed association analysis of stroke phenotypes in 10,210 cases and 12,285 199 
controls of European ancestry from Europe, United States, and Australia; most of which 200 
contributed to the METASTROKE ischaemic stoke GWAS meta-analysis – and all of which 201 
have been described previously (Table 1). 2, 12, 13 In all cases, diagnosis of stroke was based 202 
on clinical evaluation with radiological confirmation. Subtyping of stroke cases was based on 203 
the TOAST criteria; in this analysis we considered the CE, LAS and SVS subtypes.14 Of 204 
note, our SVS analysis included a large sample (1,012 cases, 970 controls) of younger onset 205 
(age<70) MRI-confirmed lacunar strokes, meaning that although we investigated all 206 
subtypes, we had most power to identify associations with SVS.  207
 11 
 208 
In stage II, we took 3 SNPs from the top 25 loci from each phenotype forward for a first in 209 
silico replication in the NINDS Stroke Genetics Network (SiGN), 2 which consisted of 7,743 210 
cases and 17,790 controls. We meta-analysed stages I and II together and identified 3 loci 211 
with p<5x10-7. Finally in stage III, we determine whether these 3 SNPs were associated with 212 
the phenotype in which they were identified (CE or SVS) by in silico replication in a large 213 
Icelandic population (deCODE; 520 SVS cases, 1,100 CE cases, 50,728 controls; stage III).  214 
 215 
Genotyping and Imputation 216 
Genotyping, quality control and imputation of all studies has been described previously.2, 3, 13 217 
All studies were genotyped on commercially available arrays from Illumina or Affymetrix and 218 
imputed to 1000 Genomes phase 1 reference panels using IMPUTE or MACH.15 Imputation 219 
quality score was assessed by calculating the ratio of the observed to the expected binomial 220 
variance of the allele dosage.  221 
 222 
Association analysis 223 
Association analysis was performed using a covariate-informed approach,11, 16 which we, and 224 
others, have implemented previously.11, 17 Briefly, the approach uses case/control status and 225 
a covariable – in this case age-at-onset – to estimate each individual’s stroke liability, which 226 
can be interpreted as their underlying propensity to stroke, on a normally-distributed scale. In 227 
this analysis cases with an earlier age-at-onset take more extreme positive values than late 228 
onset cases as, due to the lower prevalence of stroke at younger ages, they are assumed to 229 
have higher stroke liability. Conversely, controls who are older and stroke-free at age-at-230 
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observation take more extreme negative value than younger controls as they have been 231 
stroke-free for a longer time and are therefore assumed to have a lower stroke liability. 232 
In this analysis, the approach was implemented in our software, CIAO (provided at 233 
https://sites.google.com/site/mtraylor263/software/covariate-informed-gwas-analysis). 234 
Specifically, the approach taken is to model phenotype data using a continuous unobserved 235 
normally distributed quantitative trait, called the disease liability (! = !! !! − !!!!!! +! +236 !), where ! = !" + !(0,1) and ! denotes the genetic effects. Then an individual is a case 237 
(z=1) if and only if ! ≥ 0 and is a control (z=0) otherwise. !! is a parameter estimating the 238 
effect of a given covariate j on the liability scale. ! denotes the disease prevalence p at the 239 
covariate mean !! under a normal cumulative distribution function ( Φ −! = !). This model 240 
is used to approximate the effect of a disease covariate – in this case age-at-onset - on the 241 
liability scale, based on estimates of risk of ischaemic stroke by age from epidemiological 242 
data, thereby estimating !!. For this analysis, the gender-specific risk of ischaemic stroke by 243 
age from an index age of 55 was obtained from population-based estimates (1.8%, 5.4%, 244 
and 12.1% before 65, 75, and 85, respectively in women; 2.4%, 7.3%, and 12.6% before 65, 245 
75, and 85, respectively in men).18 We assumed that 20% of ischaemic stroke cases had 246 
each of the cardioembolic, small vessel or large vessel stroke subtypes, approximating 247 
proportions observed in population-based studies..19 We developed two models for our 248 
analysis; one based on the risk rates for all ischaemic stroke, and secondly for the three 249 
stroke subtypes. We used these models to calculate posterior mean liabilities after 250 
conditioning on age-at-onset for the four stroke phenotypes separately 251 
(! !|!, ! = !!!! !!! !! !!!! !!!! !"!!!! !!!!!!! !!! !! !" , !" ! = 1). Controls were modelled in the same way, but were 252 
assumed to take the posterior mean from the lower (unaffected) portion of the distribution in 253 
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the liability threshold model (! !|!, ! = !!! !!! !!! !!!! !!!! !!!!!! !!!!!! !!! !!! !" , !" ! = 0). Where age data was 254 
missing, individuals were assigned the median age value (<1% of cases). Regression was 255 
then performed on posterior liabilities (! !|!, ! ) by multiplying the number of samples by the 256 
squared correlation between the expected genotype dosage and posterior mean liabilities for 257 
each of the discovery cohorts in the four ischaemic stroke phenotypes (all IS, CE, LAS, 258 
SVS). Ancestry-informative principal components were included where appropriate, using 259 
the EIGENSTRAT procedure.20 Any residual inflation was accounted for by adjusting results 260 
by the genomic inflation factor, λ.21 In all analyses, SNPs with imputation quality score<0.7 or 261 
minor allele frequency<0.01 were excluded and meta-analysis was performed using 262 
Stouffer’s method in METAL.22 263 
 264 
Further analysis of a novel locus associated with small vessel stroke  265 
For a novel variant associated with SVS, we performed further analysis to elucidate the 266 
association for different groups based on age-at-onset. Firstly, for datasets in stage I and II, 267 
we divided the cases into quartiles based on age-at-onset and estimated the association of 268 
the SNP with each quartile using logistic regression with all controls, meta-analysing using a 269 
fixed-effects inverse variance weighted approach (data not available in BRAINS, MGH-270 
GASROS, ISGS/SWISS). Secondly, we interrogated associations at the locus in non-271 
European ancestry populations, comprising 657 small vessel African-American stroke cases 272 
and 3,251 matched controls from the NINDS Stroke Genetics Network and African or 273 
African-Caribbean ancestry individuals from the South London Ethnicity and Stroke Study 274 
(SLESS), 2, 23 and 314 SVS cases and 5,193 controls of Pakistani ancestry from the RACE 275 
study.3 We used logistic regression to evaluate the association within each group, and 276 
evaluated the overall transethnic association by meta-analysing using Stouffer’s method. 277 
 14 
 278 
In addition, we explored association of the SNP with other SVD phenotypes. We evaluated 279 
association of the SNP with 1) white matter hyperintensity volumes (WMHV) measured on 280 
T2-weighted MRI in 3,670 ischaemic stroke patients of European ancestry,24 2) in MRI-281 
defined small subcortical brain infarcts (SSBI) brain infarcts in 17,197 trans-ethnic individuals 282 
(85.7% European; 8.8% African-American; 3.5% Hispanic; 1.0% Chinese; 1.0% Malay) from 283 
community studies recruited within the neuro-CHARGE consortium (mean age 68.90 ± 284 
10.31; 1,986 with infarcts). SSBI were defined as MRI-defined brain infarcts of 3-15 mm or 3-285 
20 mm in size, located in the basal ganglia, the white matter, or the brainstem. Association 286 
analysis was performed overall, and for the subset of cases with extensive WMH burden – 287 
defined as the top age-specific quartile of WMH volume on a quantitative scale or above the 288 
age-specific median by 5-year age-categories for studies using semi-quantitative 289 
measurements of WMH burden; N=549; 3) ICH in 1,545 European ancestry cases and 1,481 290 
controls, described previously,25 and stratified according to lobar or nonlobar location.  291 
 292 
Evaluation of regulatory chromatin states, mRNA expression and DNA methylation  293 
To investigate a novel locus, we used existing resources and performed some further 294 
analyses to characterize its regulatory potential. We interrogated chromatin states and 295 
regulatory motifs from ENCODE and Epigenomics Roadmap using Haploreg v4.1.26 We also 296 
evaluated whether the associated SNP influences gene expression using GTEx portal.27 297 
Upon identifying an association between the SNP and expression of a nearby gene, we 298 
evaluated the evidence that the association signal for SVS and gene expression derives 299 
from the same causal variant using a Bayesian colocalisation test.28 Using the R coloc 300 
package (http://cran.r-project.org/web/packages/coloc), we compared 5 models for SNPs 301 
with 50Kb of our lead SNP using the approach (H0: No association with either trait; H1: 302 
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Association with SVS, not with expression; H2: Association with expression, not with SVS; 303 
H3: Association with SVS and expression, two independent SNPs; H4: Association with SVS 304 
and expression, one shared SNP). 305 
 306 
Next, we assessed whether the lead SNP (rs12445022), or 3 SNPs in linkage disequilibrium 307 
(LD) (rs4843625, rs12920915, rs12444224), influence DNA methylation levels in whole 308 
blood. We evaluated genetic associations of whole blood DNA methylation levels at selected 309 
CpG-sites profiled on the Illumina Infinium HumanMethylation450 BeadChip array in a group 310 
of 660 monozygotic (MZ) female twins (mean age 59, age range 18 to 79).  These 311 
individuals were research volunteers from the TwinsUK cohort in the United Kingdom.29 All 312 
were of European ancestry. For each CpG-site of interest we calculated the normalised 313 
methylation means for the 330 MZ twin pairs as a phenotype in the genetic analysis, and 314 
took into account covariates including smoking, BMI, age, methylation plate, and blood cell 315 
count estimates. TwinsUK imputed genotypes were obtained for the 1000 genomes 316 
reference set,30 where we excluded SNPs with Hardy–Weinberg p<1x10-4, Minor allele 317 
frequency (MAF) <5% and those with IMPUTE info value <0.8. We tested for association 318 
with our SNP, or SNPs in close LD (r2>0.6) with DNA methylation at CpG-sites. We used 319 
p<4x10-5, equivalent to a false discovery rate (FDR) <5%,31 to identify significant cis-mQTL 320 
associations. 321 
 322 
Finally, we explored genetic associations at 16q24.2 (defined as within 50Kb of rs12445022) 323 
with DNA methylation profiles in 166 human fetal brain samples (92 male, 74 female) 324 
ranging from 56–166 days post-conception initially using publically available data – which 325 
holds results for mQTL associations reaching the study-wide significance threshold 326 
(http://epigenetics.essex.ac.uk/mQTL/). Methods for this study have been published in detail 327 
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elsewhere.32 Briefly, DNA methylation levels were profiled on the Illumina Infinium 328 
HumanMethylation450 BeadChip array and SNP genotypes were obtained from the Illumina 329 
HumanOmniExpress BeadChip and imputed to 1000 Genomes phase 3 using SHAPEIT and 330 
Minimac3 via the Michigan Imputation Server.15, 33 SNP-methylation probe pairs were tested 331 
using the R package MatrixEQTL,34 including covariates to control for age, sex and ancestry-332 
informative principal components. Upon identifying a significant association at 16q24.2, we 333 
performed additional analyses (not publicly available: we gained access to the data) to test 334 
whether any of our 4 SNPs (rs12445022, rs4843625, rs12920915, rs12444224) were 335 
associated with methylation at the identified probe. We again used p<4x10-5, equivalent to a 336 
false discovery rate (FDR) <5%,31 to identify significant cis-mQTL associations. 337 
 338 
Results  339 
Association analysis 340 
In phase I association analysis we confirmed previous associations between HDAC9 and 341 
LAS (rs2107595, p=3.0x10-8) and between PITX2 and CE (rs192172299, p=2.0x10-9).3, 4 342 
Previous associations between ZFHX3 and CE and between MMP12 and LAS did not reach 343 
genome-wide significance in this analysis (rs879324, p=5.0x10-7 and rs586701, p=0.0014; 344 
respectively).11 A SNP in a region close to HABP2 previously associated with young onset 345 
ischaemic stroke was also significant, albeit not genome-wide, in this analysis (rs11196288; 346 
p=2.4x10-4).35 Genomic inflation λ and the equivalent values scaled to 1000 cases and 1000 347 
controls (λ1000),36 were well controlled across all analyses (IS, λ (λ1000) =1.05 (1.00); CE, λ (λ-348 
1000) =1.02 (1.00); LAS, λ (λ1000) =1.02 (1.00); SVS. λ (λ1000) =1.01 (1.00)). 349 
 350 
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We took 25 independent loci forward (3 SNPs in LD from each locus selected on p-value) 351 
from each analysis (IS, CE, LAS, SVS) for in silico replication in the NINDS Stroke Genetics 352 
Network study (stage II). Information on these SNPs is provided in Supplementary Tables 1-353 
4. Following this analysis , excluding previously reported associations, three loci showed 354 
significance at p<5x10-7 (two with SVS, one with CE) and one was genome-wide significant 355 
(rs12445022, p=4.4x10-8, associated with SVS). We followed up all three loci in a second in 356 
silico replication (stage III) in a large Icelandic population (deCODE). A single SNP, 357 
rs12445022, showed evidence of replication (p=0.011). When performing a meta-analysis 358 
across all populations, rs12445022 was associated with SVS at genome-wide significance 359 
(p=3.2x10-9; Figure 2). The SNP was either genotyped or well imputed (info>0.9) in all 360 
cohorts and lies in an intergenic region between Junctophilin 3 (JPH3) and Zinc Finger, 361 
CCHC Domain Containing 14 (ZCCHC14). To confirm the association with rs12445022, we 362 
repeated the analysis using logistic regression; the approach taken in a conventional GWAS. 363 
The association was validated using this method, and associations were consistent across 364 
populations (OR(95% CI)=1.16(1.10-1.22); p=1.3x10-8; heterogeneity p=0.56; Figure 3). 365 
 366 
Further analysis of a 16q24.2 novel locus associated with small vessel stroke  367 
We evaluated association of the lead SNP in different quantiles of age at stroke onset, using 368 
all controls in each analysis. The strongest associations were observed in younger onset 369 
cases, suggesting the influence of the SNP might be greatest in these individuals (Figure 4). 370 
However, this was not demonstrated statistically (p>0.05).  371 
 372 
We performed further analysis to assess whether the SVS-associated SNP influenced other 373 
manifestations of cerebral SVD. The SNP (rs12445022) was also associated with increased 374 
T2-WMHV (OR(95% CI)=1.10(1.05-1.16); p=5.3x10-5; Figures 2,5), and showed little 375 
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heterogeneity across study groups (heterogeneity p=0.58). Conversely, the SNP was not 376 
associated with ICH – neither overall, nor in subgroups divided by lobar/non-lobar location. 377 
For SSBI, the direction of effect was the same as for SVS, but the effect was weaker and 378 
non-significant (OR(95% CI)=1.05(0.97-1.14); p=0.28). For the subgroup with WMH, the 379 
effect was stronger – and similar to that observed for SVS, but was again non-significant 380 
(OR(95% CI)=1.15(0.99-1.33); p=0.076).  381 
 382 
We next evaluated the identified locus in non-European ancestry populations. The SNP had 383 
a similar frequency to Europeans in South Asians from RACE (MAF=37%), but was rarer in 384 
African ancestry populations, consisting of African-Americans from NINDS Stroke Genetics 385 
Network and United Kingdom individuals of African or African-Caribbean ethnicity from 386 
SLESS (MAF=14%). Associations with the SNP were in the same direction as in European 387 
ancestry populations (Figure 4), but did not reach statistical significance in either ancestry, 388 
reflecting the much smaller sample sizes. However, when combining data from all 389 
populations, evidence for association at the SNP (p=1.4x10-9) was stronger than in 390 
European ancestry populations alone, which might suggest a common association across 391 
populations. Indeed, there was not evidence of a significant difference in the strength of 392 
association between the European and non-European ancestry individuals (p=0.64). 393 
 394 
Regulatory chromatin states, mRNA expression and DNA methylation related to 16q24.2 395 
We used existing databases to assess the functional consequences of SNPs in the 16q24.2 396 
region. Firstly, we used the Haploreg v4.1 database to interrogate chromatin states and 397 
regulatory motifs from ENCODE and NIH Roadmap Epigenomics Mapping Consortium. 26, 37, 398 
38 The database showed that our lead SNP influences chromatin states in multiple tissues. 399 
 19 
The SNP is classified as a genic promoter in 9 tissues, an enhancer in 13 tissues and 400 
overlaps DNAse1 hypersensitivity sites in 21 tissues.  401 
 402 
Secondly, we used publicly available databases to evaluate the evidence that the lead SNP 403 
influences expression of nearby genes using the GTEx portal.27 The implicated A allele of 404 
our lead SNP (rs12445022) was associated with decreased expression of ZCCHC14 in tibial 405 
arterial tissue (p=9.4x10-7; Figure 2). We used a Bayesian colocalisation technique to assess 406 
whether the same variant drives the both the SVS association signal and mRNA expression 407 
of ZCCHC14.28 There was overwhelming evidence in support of H4 (Posterior probability = 408 
99.7%), strongly indicating that a single variant - most likely to be rs12445022 - influences 409 
both SVS and expression of ZCCHC14.  410 
 411 
Finally, we performed analyses to assess whether the lead SNP, or the 3 SNPs in LD, 412 
influence DNA methylation at CpG probes in whole blood. We found evidence that the lead 413 
SNP, and 3 SNPs in close LD (r2>0.6), influence DNA methylation at 4 nearby CpG sites 414 
(cg16596957, cg10312981, cg03020503, cg00555085; all p<4.0x10-5, Table 2). The 415 
implicated A allele of rs12445022 was associated with decreased methylation at the 416 
cg16596957 probe (beta(SE)=-0.38(0.082); p=5.3x10-6). The SNPs explained between 5-8% 417 
of the methylation variance at the given CpG sites. The same 16q24.2 region by CpG probe 418 
(cg16596957) association was also recently reported in another study in whole blood.40 In 419 
addition, we looked for an association between SNPs at the 16q24.2 locus and DNA 420 
methylation levels in fetal brains, initially using publicly available data 421 
(http://epigenetics.essex.ac.uk/mQTL/). There was a strong association with SNPs in distant 422 
LD with our lead SNP (rs8047314 ~ cg08031982; p=7.1x10-14; r2=0.16 with rs12445022). We 423 
then performed additional analyses (not publicly available: we gained access to the data) to 424 
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test if our lead SNP, or the SNPs in close LD, were associated with methylation at 425 
cg08031982. We could identify no associations that reached our significance threshold 426 
(p<4.0x10-5). However, there was a near-significant association of rs12920915 and 427 
rs4843625 with methylation at the cg08031982 probe (both p=7.8x10-5). Our lead SNP, 428 
rs12445022 was not associated (p=9.9x10-4). 429 
 430 
Discussion 431 
Genome-wide association studies in SVS have largely been disappointing. Some studies 432 
have suggested that an association with all IS at the highly pleiotropic 12q24.12 is driven by 433 
an association with SVS, 2 but no genome-wide significant associations specifically with SVS 434 
have yet been identified. Using an age-of–onset informed analysis approach we identified a 435 
novel locus at 16q24.2 associated with SVS. The SNP was also associated using a standard 436 
logistic regression approach, but was less significant – a difference of almost an order of 437 
magnitude (p=3.2x10-9 compared to p=1.3x10-8). In addition, the association was stronger 438 
with younger onset SVS, suggesting a greater influence in these individuals. We tested 439 
whether the 16q24.2 association extends to other cerebral SVD related phenotypes. We 440 
showed that the same locus also influences WMH, and may have a similar effect on MRI-441 
defined subcortical brain infarcts from prospective studies, although the association did not 442 
reach significance in our analysis. However, the locus does not appear to influence risk of 443 
ICH. A SNP in the same 16q24.2 region (rs4081947), in partial LD with our SNP (r2=0.28), 444 
was also recently reported to be associated with migraine in a large GWAS meta-analysis. 41 445 
These data provide strong supportive evidence that this 16q24.2 locus harbours variants that 446 
influence diseases of the cerebral vasculature.  447 
 448 
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Identifying the mechanisms by which GWAS associations influence disease risk presents 449 
additional challenges. In this case, the underlying mechanism and the specific genes 450 
implicated remains uncertain. Interrogation of mRNA expression data points to the lead SNP 451 
influencing expression of the nearest gene, ZCCHC14. This gene is ubiquitously expressed, 452 
but is highly expressed in arterial tissues and in the brain. However, its function is not well 453 
characterized. Zinc fingers of the CCHC-type contain an 18 digit residue found in the 454 
nucleocapsid of retroviruses, and therefore may be important in viral response. Other 455 
plausible candidate genes reside nearby. The locus lies around 1Mb away from genes 456 
encoding forkhead box proteins including FOXC2, FOXL1, and FOXF1. These proteins, 457 
particularly the closely related FOXC1 – a paralogue of FOXC2, have been implicated in 458 
Mendelian forms of SVS.42 We found no evidence linking our SNP to expression of these 459 
genes. However, the function of these proteins changes dramatically between early 460 
development and in adult tissues,43 which might explain the absence of an association. This, 461 
coupled with the fact that FOXF2 variants have also recently been implicated in ischaemic 462 
stroke,44 make forkhead box proteins exciting targets for follow-up experiments. 463 
 464 
Assessing DNA methylation, the process by which methyl groups are added to DNA thereby 465 
modifying its function, offers another potential method for mechanistic insight. This 466 
epigenetic process influences gene expression and regulation in humans, and may be 467 
particularly relevant for diseases such as stroke where gene-environment interactions are 468 
likely play an important role in pathogenesis.45 Substantial inter-individual variation exists 469 
with respect to age and tissue type.46 However, an important emerging mechanism 470 
influencing methylation is local sequence content.47 Notably, recent studies have shown that 471 
GWAS findings from stroke-relevant traits such as blood pressure are likely to act by 472 
influencing DNA methylation.48 This may be particularly relevant for SVS, in which 473 
environmental and other vascular risk factors such as hypertension are important and have 474 
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been shown to interact with disease risk.49 We evaluated whether our associated SNP 475 
(rs12445022), or SNPs in close LD, influence methylation of nearby CpG sites. We found 476 
evidence from whole blood that the same genetic variation influences DNA methylation. 477 
SNPs in distant LD also influenced DNA methylation at a different probe (cg08031982) in the 478 
fetal brain. Further evidence comes from published studies in lung, breast, and kidney 479 
tissues,31 as well as in utero,50 all of which have shown that the genetic variation at the same 480 
16q24.2 region influences methylation at the cg08031982 probe. Interestingly, the CpG sites 481 
influenced by the locus appear to differ by tissue, with different probes affected in whole 482 
blood compared to fetal brain. This might imply tissue-specific functional consequences of 483 
the locus and therefore highlights the importance of performing follow-up experiments in 484 
appropriate tissues. Based on the evidence presented here, we can only speculate on how 485 
genetic variation at the locus leads to increased risk of SVS. One hypothesis is that 486 
expression of ZCCHC14, or other proteins, is mediated through altered methylation of the 487 
probes identified. This might occur, in part, in response to environmental stimuli. Evaluating 488 
these hypotheses in a relevant tissue type will be an important future analysis to identify the 489 
causal mechanisms leading to SVS.  490 
 491 
This study has limitations. Our results suggested that the association may be present in 492 
other ethnicities, but we had an insufficient number of cases to establish common risk 493 
conclusively. Follow-up studies are therefore required in other ethnic groups. In addition, 494 
downstream functional experiments will be required to determine the consequences of the 495 
identified association. The mRNA expression and methylation analyses presented herein 496 
were constrained by available tissue types. Validation of the findings in more disease 497 
relevant tissue types such as cerebral small vessels therefore represent important follow-up 498 
analyses, although obtaining such tissue in a state to allow mRNA studies is very 499 
challenging. We performed mRNA expression and methylation analyses using either the 500 
 23 
lead SNP (rs12445022) or 3 LD SNPs. The results should be interpreted with the limitation 501 
that we cannot be certain that any of these SNPs is the causal variant. Radiological 502 
confirmation of SVS in this study was performed using either CT or MRI. Evidence shows 503 
that MRI is considerably more reliable at identifying SVS. Replication of the association in an 504 
MRI-confirmed population may therefore provide a more accurate estimate of the effect of 505 
the locus on SVS risk. Similarly, interrogation of causative classification system (CCS) 506 
definitions of SVS may provide further insights. 51 Another method of interrogating the 507 
combined influence of age and genotype is by testing for an interaction. In this analysis, we 508 
were unable to do this as age was not available in some sets of controls (e.g WTCCC2). 509 
 510 
In this large genome-wide meta-analysis using an age-at-onset informed approach, we have 511 
identified the first genome-wide significant locus that is associated solely with SVS. Our 512 
findings, which point to subtle changes in gene expression and DNA methylation influencing 513 
disease risk, show that strategies that account for different liability across disease related 514 
covariates such as age can identify novel associations with disease.   515 
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Table 1 – Ischaemic Stroke Study part ic ipants 558 
Population IS CE LAS SVS Controls % cases with MRI 
Age of cases 
(mean(s.d)) 
Stage I Populations 
ASGC 1,162 240 421 310 1,244 43.0% 72.9 (13.2) 
WTCCC2-Germany 1,174 330 346 106 797 83.0% 66.7 (12.9) 
WTCCC2-UK 2,374 474 498 460 5,175 37.2% 72.2 (12.5) 
Milano 366 64 73 25 407 86.7% 57.4 (15.6) 
DNA-lacunar / GENESIS 1,287 80 64 1,012 970 100.0% 59.6 (12.0) 
LSS 455 157 70 55 455 89.0% 67.7 (14.5) 
ISGS / SWISS 1,014 235 217 187 1,370 83.0% 66.5 (13.6) 
BRAINS 361 29 120 97 444 30.8% 74.4 (14.2) 
MGH-GASROS 294 106 68 23 376 60.0% 66.7 (14.5) 
VISP 1,723 - - - 1,047 47.0% 68.0 (10.7) 
Total (discovery) 10,210 1,715 1,877 2,275 12,285   
Stage II populations 
NINDS Stroke Genetics 
Network 7,743 2,001 1,130 1,408 17,970 62.0% 66.3 (14.8) 
Stage III populations 
deCODE - 1,100 - 520 20,473 NA 72.7 (11.6) 
TOTAL 17,953 4,816 3,007 4,203 50,728   
 559 
IS, all ischaemic stroke; CE, cardioembolic stroke; LAS, large artery stroke; SVS, small 560 
vessel stroke; ASGC, Australian Stroke Genetics Collaborative; WTCCC2, Wellcome Trust 561 
Case Control Consortium 2; LSS, Leuven Stroke Study; BRAINS, Bio-repository of DNA in 562 
stroke; MGH-GASROS, The MGH Genes Affecting Stroke Risk and Outcome Study; VISP, 563 
The Vitamin Intervention for Stroke Prevention Trial; NA, information not available.  564 
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Table 2 – Signif icant associat ions between rs12445022 and LD SNPs 565 
(r2>0.6) with c is-methylat ion probes in whole b lood 566 
 567 
SNP Variant SNP BP CpG Probe Probe BP RA beta (SE) R2 P-value 
rs12445022 87,575,332 cg16596957 87,575,151 A -0.38 (0.082) 0.058 5.3x10-6 
rs4843625 87,576,996 cg16596957 87,575,151 C -0.33 (0.075) 0.053 1.3x10-5 
rs4843625 87,576,996 cg10312981 87,577,304 C 0.39 (0.074) 0.077 1.9x10-7 
rs4843625 87,576,996 cg03020503 87,577,656 C 0.35 (0.075) 0.059 5.0x10-6 
rs4843625 87,576,996 cg00555085 87,616,248 C 0.34 (0.075) 0.057 6.6x10-6 
rs12920915 87,577,521 cg16596957 87,575,151 T -0.38 (0.075) 0.069 7.3x10-7 
rs12920915 87,577,521 cg10312981 87,577,304 T 0.38 (0.075) 0.068 1.0x10-6 
rs12920915 87,577,521 cg03020503 87,577,656 T 0.34 (0.076) 0.055 1.1x10-5 
rs12920915 87,577,521 cg00555085 87,616,248 T 0.33 (0.076) 0.051 2.2x10-5 
rs12444224 87,580,855 cg16596957 87,575,151 T -0.38 (0.075) 0.068 8.0x10-7 
rs12444224 87,580,855 cg10312981 87,577,304 T 0.38 (0.075) 0.069 8.7x10-7 
rs12444224 87,580,855 cg03020503 87,577,656 T 0.35 (0.076) 0.054 1.1x10-5 
rs12444224 87,580,855 cg00555085 87,616,248 T 0.32 (0.076) 0.050 2.6x10-5 
BP, base posit ion; RA, reference al le le;  R2,  proport ion of methylat ion 568 
var iance explained by respect ive genotype.  569 
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Figure Legends 570 
Figure 1 – Flow chart  of  analyses performed 571 
Figure 2 – Associat ions at 16q24.2 with A) smal l  vessel s troke, B) cerebral  572 
white matter hyper intensi t ies,  C) mRNA expression of ZCCHC14; and D) 573 
Gene Locat ions and associat ions of the locus with DNA methylat ion 574 
SVS, small vessel stroke; WMH, white matter hyperintensities; ZCCHC14, Zinc Finger, 575 
CCHC Domain Containing 14; JPH3, Junctophilin 3; meQTL, methylation quantitative trait 576 
locus. 577 
Figure 3 – Forest Plot of  Associat ions with rs12445022 under a logis t ic  578 
regression model 579 
 580 
Figure 4 – Associat ion of  rs12445022 with smal l  vessel s troke by quart i les of  581 
age-at-s troke onset in Europeans 582 
 583 
Figure 5 – Associat ions with rs12445022 for s troke and cerebral  smal l  vessel 584 
disease phenotypes 585 
 586 
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